1. What they do

Zimmer Biomet designs, manufactures, and sells orthopedic reconstructive products (hip, knee, shoulder, elbow), spine and dental implants, trauma fixation, and surgical instruments. Warsaw, Indiana — the “Orthopedic Capital of the World” — hosts ZBH HQ and major manufacturing operations.

2. What customers actually report

• Durom Cup hip implant — Zimmer voluntarily suspended sales in 2008 after high revision rates; class actions and individual lawsuits followed for years. The FDA-classified recall and Zimmer’s settlement program are documented in court filings.
• NexGen Knee class actions — multidistrict litigation (MDL 2272) consolidated NexGen knee cases in 2011; outcomes varied case-by-case.
• FCPA settlements — Biomet (2012) and Zimmer Biomet (2017) DOJ deferred-prosecution and consent agreements are publicly available on the DOJ FCPA enforcement page.
• Patient outcomes are clinical, not consumer-retail — complaint data routes through surgeons and hospitals, then to FDA MAUDE; direct-to-consumer complaint volume is small.

3. What the data shows

• SEC 10-K (2024): $7.68B revenue; net income ~$903M.
• FDA MAUDE database: thousands of adverse-event reports filed across Zimmer Biomet device categories — volume is large but is also industry-typical for high-volume orthopedic implants.
• FDA recall database: multiple Class I and Class II recalls over the past decade.
• DOJ FCPA — 2012 Biomet ($22.8M) and 2017 Zimmer Biomet ($30.5M) settlements.

4. How they handle complaints

Patient complaints route through orthopedic surgeons to Zimmer Biomet Medical Affairs and the FDA MedWatch reporting system. Litigation settlements (Durom Cup, NexGen) created compensation programs but required individual case management. FCPA-related compliance program is post-2017 monitored.

5. IBE Score: 4/10 — reasoning

Significant Indiana employer and a clinical-quality manufacturer; offset by Durom Cup, NexGen, and FCPA history. 4/10 reflects the weight of past recall and bribery settlements. The company has demonstrably matured its compliance program post-2017 but the historical pattern is significant.

6. Verified public sources

1. Zimmer Biomet 2024 Annual Report (10-K)
2. FDA MAUDE Database
3. FDA recalls — Zimmer Biomet products
4. DOJ FCPA — Biomet Inc. 2012 settlement
5. DOJ FCPA — Zimmer Biomet 2017 settlement
6. Durom Cup MDL court filings

7. What this review is, and what it isn’t

• Independent. No payment, sponsorship, or advertising relationship between IBE and the reviewed business.
• Public-record only. Every claim above traces to a source listed in section 6. Where data couldn’t be verified, the review either omits the claim or labels it as a pattern reported by customers (not a finding).
• Not legal or medical advice. If a specific transaction went wrong, document it in writing, escalate to the company first, then to the relevant regulator (Indiana AG, IDOI, IURC, CFPB, FDA, NHTSA, etc.) as appropriate.
• Updated as evidence comes in. If you have a primary-source document that changes any claim above — a court filing, a regulatory order, a settlement agreement — submit it via the tip form. Reviews are revised when verifiable evidence warrants.

This review reflects publicly available information as of the review date listed above. IBE has no commercial relationship with Zimmer Biomet Holdings or its parent entities.